In this study, by analyzing changes of intracellular ROS levels, we explored the role of FHC, an important antioxidant enzyme, in the development of resistance to cisplatin-based therapy in ovarian cancer cells. This evidence concerns the gene FTH1 and ovarian carcinoma.